补虚祛痰法治疗慢性阻塞性肺疾病稳定期临床疗效的Meta分析

An effective Meta-analysis of treating COPD during stable phase by the Buxu Qutan therapy

目的:系统评价补虚祛痰法治疗慢性阻塞性肺疾病稳定期的临床疗效和安全性。方法:计算机检索CBM,CNKI,万方,VIP,Pub Med,Cochrane Library,MEDLINE,查以"补虚祛痰法治疗COPD稳定期"的随机或半随机对照试验。按照Cochrane系统评价方法筛选文献、提取资料并评价文献质量后,采用Rev Man 5.3软件行Meta分析。结果:13篇文献被纳入,包括1160例受试者。Meta分析结果显示补虚祛痰法为主的各试验组的总有效率、肺功能、生活质量评分及血清免疫指标较常规治疗对照组明显改善,所有研究均未提及退出或失访。结论:由于所有纳入研究的文献的质量均不高,故此系统评价产生偏倚风险较高,合并分析的结果可靠程度均不高。因此,补虚祛痰法治疗慢阻肺稳定期患者的疗效和安全性仍需更多高质量的临床研究验证。

Objective： To systematically evaluate the effciency and safety of the Buxu Qutan therapy on COPD during stable phase. Methods： Randomized or semi randomized controlled trials of treating COPD during stable stage by the Buxu Qutan therapy were retrieved in CBM, CNKI, WanFang, VIP, PubMed, Cochrane Library, MEDLINE. According to the Cochrane system evaluation, by screening literatures, extracting information and evaluating the quality of literatures, a Meta-analysis was performed by RevMan 5.3 software. Results： 13 literatures （1160 subjects） were selected. The results of Meta-analysis showed that the total effciency, pulmonary function, quality of life score and serum immune index in all treatment groups （treating by the Buxu Qutan therapy） were more obviously improved than the control group, with no quit or withdrawal. Conclusion： Because the quality of all the included studies was not high, risk of bias by systematic evaluation was higher, and the reliability of analyzing results wasn’t high. Therefore, the effciency and safety of the Buxu Qutan therapy on COPD during stable phase still needed to be veriifed by more high quality clinical researches.